=== Generating (published_papers) ===
=== Generating (teaching_experience) ===
=== Generating (education) ===
=== Generating (research_experience) ===
=== Generating (awards) ===
=== Generating (association_memberships) ===
=== Generating (presentations) ===
==== begin registerFile(/WWW/pub2/data/ERD/person/405953/researchmap/published_papers-propagate.jsonl) ====
line:1, {"insert":{"user_id":"R000099366","type":"published_papers","id":"54608605"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/42527092","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=467754","label":"url"}],"paper_title":{"en":"Development of Novel Schiff BaseTyrosine Kinase Inhibitor Conjugates that Enhance the Effects of ALA-PDT","ja":"Development of Novel Schiff BaseTyrosine Kinase Inhibitor Conjugates that Enhance the Effects of ALA-PDT"},"authors":{"en":[{"name":"Shinohara Yusei"},{"name":"Abe Chiaki"},{"name":"Endo Yoshio"},{"name":"Yamada Hisatsugu"},{"name":"Uto Yoshihiro"}],"ja":[{"name":"篠原 侑成"},{"name":"安部 千秋"},{"name":"遠藤 良夫"},{"name":"山田 久嗣"},{"name":"宇都 義浩"}]},"description":{"en":"Photodynamic therapy (PDT) using 5-aminolevulinic acid (ALA) is a widely accepted and minimally invasive treatment for various cancers. The Schiff base derivative N-3',5'-dichloro-2'-hydroxybenzylidene-2-chloro-4-nitroaniline (TX-816) markedly enhances the efficacy of ALA-based PDT (ALA-PDT) by promoting intracellular accumulation of protoporphyrin IX (PpIX). However, TX-816 is unstable in aqueous solutions and rapidly hydrolyzes into the active agent 3, 5-dichlorosalicylaldehyde (DCSA) and 2-chloro-4-nitroaniline, thereby complicating its clinical application. We synthesized UTX-144 (a dasatinib derivative) and UTX-148 (a gefitinib derivative) by conjugating the tyrosine-kinase inhibitors dasatinib or gefitinib with DCSA via a Schiff base. These novel ALA-PDT sensitizers conjugate tyrosine kinase inhibitors (TKIs) that target ATP-binding cassette subfamily G member 2 (ABCG2), a PpIX efflux transporter, with DCSA via a Schiff base. UTX-144 and UTX-148 showed strong ALA-PDT sensitization effects when used in combination with ALA, thereby increasing intracellular PpIX accumulation. This study successfully developed the novel ALA-PDT sensitizers UTX-144 and UTX-148.","ja":"Photodynamic therapy (PDT) using 5-aminolevulinic acid (ALA) is a widely accepted and minimally invasive treatment for various cancers. The Schiff base derivative N-3',5'-dichloro-2'-hydroxybenzylidene-2-chloro-4-nitroaniline (TX-816) markedly enhances the efficacy of ALA-based PDT (ALA-PDT) by promoting intracellular accumulation of protoporphyrin IX (PpIX). However, TX-816 is unstable in aqueous solutions and rapidly hydrolyzes into the active agent 3, 5-dichlorosalicylaldehyde (DCSA) and 2-chloro-4-nitroaniline, thereby complicating its clinical application. We synthesized UTX-144 (a dasatinib derivative) and UTX-148 (a gefitinib derivative) by conjugating the tyrosine-kinase inhibitors dasatinib or gefitinib with DCSA via a Schiff base. These novel ALA-PDT sensitizers conjugate tyrosine kinase inhibitors (TKIs) that target ATP-binding cassette subfamily G member 2 (ABCG2), a PpIX efflux transporter, with DCSA via a Schiff base. UTX-144 and UTX-148 showed strong ALA-PDT sensitization effects when used in combination with ALA, thereby increasing intracellular PpIX accumulation. This study successfully developed the novel ALA-PDT sensitizers UTX-144 and UTX-148."},"publication_date":"2026-08","publication_name":{"en":"Anticancer Research","ja":"Anticancer Research"},"volume":"46","number":"8","starting_page":"4689","ending_page":"4698","languages":["eng"],"referee":true,"identifiers":{"doi":["10.21873/anticanres.18325"],"issn":["1791-7530"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
==== end registerFile(/WWW/pub2/data/ERD/person/405953/researchmap/published_papers-propagate.jsonl, tOuR0KABn_HdSsNVt-RZ) ====
====== BulkResult(R000099366, tOuR0KABn_HdSsNVt-RZ) : Begin ======
--- error

--- success
====== BulkResult(R000099366, tOuR0KABn_HdSsNVt-RZ) : End ======